HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A. Yu, Pasi A. Jänne, Kiyotaka Yoh et al.|Journal of Clinical Oncology|2023Cited by 224
A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors.Wael A. Harb, Srinivasu Poondru, C. Sessa et al.|Journal of Clinical Oncology|2011Cited by 7
OA05.03 Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFRTKI and Platinum-Based Chemotherapy: HERTHENA-Lung01Helena A. Yu, Pasi A. Jänne, Yasushi Goto et al.|Journal of Thoracic Oncology|2023Cited by 1